Pacific Biosciences

Update in progress

PACB (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions for genetically complex problems. It provides SMRT-based long‑read systems and consumables, including SMRTbell libraries, ligases, buffers, exonucleases, and polymerase binding kits. Instruments such as Revio, Vega, and Sequel perform real-time sequencing on SMRT cells and support short‑read work. Serving global research, clinical, and commercial labs, it collaborates with DNAstack on HiFi WGS data. Formerly Nanofluidics, Inc.; renamed 2005. Based in Menlo Park, incorporated 2000.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive